STA Pharmaceutical Co Ltd (WuXi STA) disclosed on Thursday the CMC based development and manufacturing of innovative oncology drugs under a strategic partnership with Antengene Corporation, a biopharmaceutical company focused on the development of new drugs in China and the Asia-Pacific region.
Under the terms of the agreement, Antengene will receive an integrated solution in process R&D and manufacturing using the MAH scheme to accelerate new drug development from WuXi STA.
The collaboration will include both clinical stage and commercial projects, commencing with Phase II/III candidate ATG-008 and then expanding into solid tumor, hematological tumor and viral infection. WuXi STA will provide process R&D and manufacturing from APIs to drug product. Antengene and WuXi STA will explore and expand the collaboration to commercial stage assets as Antengene prepares for the commercialisation of its late-stage pipeline agents.
In addition, ATG-008 is currently in multi-regional clinical trial (MRCT) for the treatment of hepatitis B virus positive (HBV+) advanced hepatocellular carcinoma (HCC) patients (TORCH study). Patient enrollment started in July 2018, stated the partnership.
STA Pharmaceutical Co Ltd (WuXi STA) a pharmaceutical development and manufacturing company and a subsidiary of WuXi AppTec.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder